| Net income | -505.16K |
| Depreciation and amortization | 104.93K |
| Gain on the disposal of assets | |
| Stock-based compensation | 42.6K |
| Derivative financial instrument | |
| Accounts receivable | -230.62K |
| Prepaid expenses and other assets | 4.93K |
| Accounts payable and accrued expenses | 490.69K |
| Accrued payroll | 316.55K |
| Unearned revenue | -265.4K |
| Total adjustments | 474.13K |
| Net cash provided by operating activities | -31.03K |
| Purchase of property and equipment | -21.07K |
| Acquisition of patents | -4.69K |
| Net cash used in investing activities | -25.76K |
| Proceeds from the exercise of warrants for common stock | |
| Proceeds from the exercise of stock options for common stock | |
| Withholding taxes paid on cashless exercise of stock options | |
| Cash dividends on series B preferred stock | |
| Net cash provided by (used in) financing activities | -68.17K |
| Net decrease in cash | -124.96K |
| Beginning of period | 2.43M |
| End of period | 2.31M |
| Issuance of restricted awards in settlement of accrued liability for for board fees | |
| Cashless exercise of stock options | |
| Cashless exercise of warrants | |
| Reclassification of derivative liabilities upon exercise of warrants to additional paid in capital | |